ReviewJournal of clinical medicine2021
Outcomes Related to Percutaneous Nephrostomies (PCN) in Malignancy-Associated Ureteric Obstruction: A Systematic Review of the Literature.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Effect of initial drainage method on retrograde intrarenal surgery outcomes in acute calcular pyelonephritis: a prospective comparative study.Urolithiasis · 2026Trial
- Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications.Frontiers in oncology · 2026Article
- Bladder metastasis from gastric cancer presenting as acute post-renal obstruction during immunotherapy: a case report.Frontiers in oncology · 2026Article
- Malignant upper urinary tract obstruction in cancer patients: A systematic review.BJUI compass · 2024Review
- Management of malignant ureteric obstruction with ureteric stenting or percutaneous nephrostomy.The British journal of surgery · 2024Article
- Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer.Current urology · 2023Article
- Serum creatinine trajectory after drainage of kidneys with bilateral malignant ureteral obstruction: a prospective non-randomized comparative study.BMC urology · 2023Article
- Acute kidney injury due to bilateral malignant ureteral obstruction: Is there an optimal mode of drainage?World journal of nephrology · 2022Review
- Predictors of nadir serum creatinine after drainage of bilaterally obstructed kidneys due to different etiologies.International urology and nephrology · 2022Article
- Special Issue 'Minimally Invasive Urological Procedures and Related Technological Developments'.Journal of clinical medicine · 2021Article
- Therapeutic advances in ureteral stricture: lessons from radiation-induced fibrosis to regenerative strategies-a narrative review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant ureteric obstruction occurs in a variety of cancers and has been typically associated with a poor prognosis. Percutaneous nephrostomy (PCN) can potentially help increase patient longevity by establishing urinary drainage and treating renal failure. Our aim was to look at the outcomes of PCN in patients with advanced cancer and the impact on the patients' lifespan and quality of life. MATERIALS AND
methodsA literature review was carried out for articles from 2000 to 2020 on PCN in patients with advanced malignancies, using MEDLINE, EMBASE, Scopus, CINAHL, Cochrane Library, clinicaltrials.gov, and Google Scholar. All English-language articles reporting on a minimum of 20 patients who underwent PCN for malignancy-associated ureteric obstruction were included.
resultsA total of 21 articles (1674 patients) met the inclusion criteria with a mean of 60.2 years (range: 21-102 years). PCN was performed for ureteric obstruction secondary to urological malignancies (
conclusionsPatients with advanced malignancies who need PCN tend to have a survival rate under 12 months and spend a large proportion of this time in the hospital. Although the advent of newer chemotherapy and immunotherapy options has changed the landscape of managing advanced cancer, decisions on nephrostomy must be balanced with their survival and quality of life, which must be discussed with the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.